Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
about
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.Duration of antimicrobial therapy in community acquired pneumonia: less is morePharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh modelTelithromycin in lower respiratory tract infections.Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumoniaThe emerging role of atypical pathogens in community-acquired pneumonia.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs varyOral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis.Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.Factors affecting gentamicin penetration in lower extremity ischemic tissues with ulcers.
P2860
Q24813259-D1A6EA39-DCDD-4526-B9DC-184D2E8DAC9FQ26828493-CF5AED0E-1213-4EBF-872B-F2640608006FQ33555366-127AE84B-849F-4BCB-BB72-3762C19DCE31Q36895727-34713AAF-16D4-4019-8E90-19ACBBAF3B3BQ36936597-2C3A922F-6C78-47B2-8CBE-D133EF18BFE1Q37116814-8C4ECC75-01D0-4A98-B3E0-FB5C5607FCC5Q37872805-7CBB0AE5-174E-4301-887E-18737641E7BFQ37927017-5B76C481-E113-4928-8738-91927AA740ECQ39390126-D469BEE4-4AA9-4951-866D-3D62B9BDCD02Q40140019-1B8D3496-B314-4149-99E5-FD2FC450065BQ42252396-A4005867-AA0A-4D66-8AAC-397CBEC3A654Q44518070-368C0194-FCA9-4E02-8FE9-16DE5A85E007Q51100124-7F0A88D1-2755-407B-A54C-B49770A0A3D3Q51423932-AC15EDE2-7814-4398-8383-D4FBFAFC5EA1
P2860
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@ast
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@en
type
label
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@ast
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@en
prefLabel
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@ast
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@en
P2093
P2860
P1476
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
@en
P2093
A Andremont
C Cantalloube
C Muller-Serieys
F Lemaitre
P2860
P304
P356
10.1128/AAC.45.11.3104-3108.2001
P407
P577
2001-11-01T00:00:00Z